G. Jeannin

1.3k total citations · 1 hit paper
21 papers, 840 citations indexed

About

G. Jeannin is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, G. Jeannin has authored 21 papers receiving a total of 840 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 16 papers in Pulmonary and Respiratory Medicine and 8 papers in Molecular Biology. Recurrent topics in G. Jeannin's work include Lung Cancer Treatments and Mutations (11 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Colorectal Cancer Treatments and Studies (4 papers). G. Jeannin is often cited by papers focused on Lung Cancer Treatments and Mutations (11 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Colorectal Cancer Treatments and Studies (4 papers). G. Jeannin collaborates with scholars based in France, United Kingdom and Brazil. G. Jeannin's co-authors include Lucio Crinò, Fábio Franke, Paul D. Smith, Alice T. Shaw, Pasi A. Jänne, José Rodrigues Pereira, Lynda Grinsted, Victoria Zazulina, Carlos H. Barrios and Johan Vansteenkiste and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and British Journal of Cancer.

In The Last Decade

G. Jeannin

20 papers receiving 821 citations

Hit Papers

1 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study

2012 512 citations Pasi A. Jänne, Alice T. Shaw et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
G. Jeannin France	9	543	465	408	165	105	21	840
Jordi Bertrán-Alamillo Spain	14	514 0.9×	472 1.0×	437 1.1×	299 1.8×	82 0.8×	33	838
Mary Ann Melnick United States	9	676 1.2×	586 1.3×	491 1.2×	261 1.6×	89 0.8×	14	977
Azusa Tanimoto Japan	16	451 0.8×	373 0.8×	366 0.9×	166 1.0×	93 0.9×	42	696
Junpei Takashima Japan	4	718 1.3×	604 1.3×	483 1.2×	210 1.3×	104 1.0×	17	946
Atsuko Ogino Japan	10	673 1.2×	527 1.1×	498 1.2×	176 1.1×	131 1.2×	18	917
José Rodrigues Pereira Brazil	9	622 1.1×	541 1.2×	419 1.0×	166 1.0×	85 0.8×	16	915
Lyudmila Bazhenova United States	16	563 1.0×	534 1.1×	270 0.7×	114 0.7×	64 0.6×	83	749
Ken Uchibori Japan	15	614 1.1×	567 1.2×	360 0.9×	156 0.9×	64 0.6×	59	885
Satoshi Yoda Japan	14	661 1.2×	490 1.1×	646 1.6×	351 2.1×	92 0.9×	27	1.1k
Bethany Pitcher Canada	16	402 0.7×	516 1.1×	337 0.8×	237 1.4×	104 1.0×	27	832

Countries citing papers authored by G. Jeannin

Since Specialization

Citations

This map shows the geographic impact of G. Jeannin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. Jeannin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. Jeannin more than expected).

Fields of papers citing papers by G. Jeannin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G. Jeannin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. Jeannin. The network helps show where G. Jeannin may publish in the future.

Co-authorship network of co-authors of G. Jeannin

This figure shows the co-authorship network connecting the top 25 collaborators of G. Jeannin. A scholar is included among the top collaborators of G. Jeannin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G. Jeannin. G. Jeannin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gobbini, Élisa, Alexandra Langlais, Pascale Missy, et al.. (2025). Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDS. European Journal of Cancer. 225. 115560–115560.

Garinet, Simon, Caroline Léger, Fabrice Barlési, et al.. (2024). STK11/LKB1 alterations worsen the poor prognosis of KRAS mutated early-stage non-squamous non-small cell lung carcinoma, results based on the phase 2 IFCT TASTE trial. Lung Cancer. 190. 107508–107508. 2 indexed citations

Damotte, Diane, Barbara Burroni, Audrey Mansuet‐Lupo, et al.. (2024). Multiplex analysis of the immune environment before and after neoadjuvant durvalumab as a prognostic factor in resectable non-small cell lung cancer (NSCLC) in the IFCT-1601 IONESCO phase 2 trial.. Journal of Clinical Oncology. 42(16_suppl). 8022–8022. 1 indexed citations

Pereira, Bruno, et al.. (2023). Oligroprogression sous nivolumab du cancer bronchique non à petites cellules métastatiques traitées par radiothérapie. Bulletin du Cancer. 110(12). 1234–1243. 1 indexed citations

Véronèse, Lauren, G. Jeannin, Henri Janicot, et al.. (2022). Telomere Status of Advanced Non-Small-Cell Lung Cancer Offers a Novel Promising Prognostic and Predictive Biomarker. Cancers. 15(1). 290–290. 3 indexed citations

Wislez, Marie, Julien Mazières, A. Lavolé, et al.. (2022). Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO). Journal for ImmunoTherapy of Cancer. 10(10). e005636–e005636. 73 indexed citations

Ricordel, Charles, J. Hureaux, G. Jeannin, et al.. (2020). Encephalitis related to immunotherapy for lung cancer: Analysis of a multicenter cohort. Lung Cancer. 143. 36–39. 23 indexed citations

Wislez, Marie, Julien Mazières, A. Lavolé, et al.. (2020). 1214O Neoadjuvant durvalumab in resectable non-small cell lung cancer (NSCLC): Preliminary results from a multicenter study (IFCT-1601 IONESCO). Annals of Oncology. 31. S794–S794. 40 indexed citations

Auliac, J.B., S. Bayle, Pascal Dô, et al.. (2020). Efficacy of Dabrafenib Plus Trametinib Combination in Patients with BRAF V600E-Mutant NSCLC in Real-World Setting: GFPC 01-2019. Cancers. 12(12). 3608–3608. 14 indexed citations

10.

Jeannin, G., P. Merle, Henri Janicot, et al.. (2015). Combined treatment modalities in Pancoast tumor: results of a monocentric retrospective study.. PubMed. 4(4). 39–39. 5 indexed citations

11.

Jänne, Pasi A., Ian C. P. Smith, Gael McWalter, et al.. (2015). Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer. British Journal of Cancer. 113(2). 199–203. 59 indexed citations

12.

Jeannin, G., et al.. (2015). Choriorétinopathie séreuse multifocale secondaire à l’utilisation des inhibiteurs MEK : illustration et exemple de prise en charge à travers 2 cas. Journal Français d Ophtalmologie. 39(1). 55–63. 2 indexed citations

13.

Pujol, Jean-Louis, A. Lavolé, B. Mennecier, et al.. (2014). Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: Results from the IFCT-0802 trial.. Journal of Clinical Oncology. 32(15_suppl). 7505–7505. 3 indexed citations

14.

Toffart, Anne‐Claire, Jean‐François Timsit, S. Couraud, et al.. (2013). Immunohistochemistry evaluation of biomarker expression in non-small cell lung cancer (Pharmacogenoscan study). Lung Cancer. 83(2). 182–188. 15 indexed citations

15.

Jänne, Pasi A., Alice T. Shaw, José Rodrigues Pereira, et al.. (2012). Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. The Lancet Oncology. 14(1). 38–47. 512 indexed citations breakdown →

16.

Jänne, Pasi A., Alice T. Shaw, José Rodrigues Pereira, et al.. (2012). Efficacy and Patient (PT)-Reported Outcomes (PROS) aith Selumetinib (AZD6244, ARRY-142866; SEL) + Docetaxel (DOC) in Kras-Mutant Advanced Non-Small Cell Lung Cancer (NSCLC): A Randomized, Phase II Trial. Annals of Oncology. 23. ix403–ix403. 2 indexed citations

17.

Jänne, Pasi A., Alice T. Shaw, José Rodrigues Pereira, et al.. (2012). Phase II double-blind, randomized study of selumetinib (SEL) plus docetaxel (DOC) versus DOC plus placebo as second-line treatment for advanced KRAS mutant non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 30(15_suppl). 7503–7503. 30 indexed citations

18.

Soubrier, Martin, G. Jeannin, Jean Louis Kémény, et al.. (2008). Organizing pneumonia after rituximab therapy: Two cases. Joint Bone Spine. 75(3). 362–365. 42 indexed citations

19.

Jeannin, G., et al.. (2008). Une cause exceptionnelle de chylothorax : l’amylose primitive. Revue des Maladies Respiratoires. 25(5). 601–604. 3 indexed citations

20.

Chabrot, P., G. Jeannin, Marc Filaire, et al.. (2008). Sarcome intimal de l’artère pulmonaire. Journal des Maladies Vasculaires. 33(1). 39–44. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact